Analogue insulin is a sub-group of human insulin. Analogue insulin is laboratory grown but genetically altered to create either a more rapid acting or more uniformly acting form of the insulin.
This can have advantages for blood sugar management
Analogue insulins have been available since just before the start of the new millennium.
HOW IS HUMAN ANALOGUE INSULIN PRODUCED?
Similar to human insulin , analogue insulin is laboratory created by growing insulin proteins within E-coli bacteria (Escherichia coli).
The process goes further through changing the order of amino acids to allow the insulin to be used by the body either more rapidly or more uniformly by the body than with regular human insulin.
This type of process is known as undergoing ‘recombinant DNA’ technology.
WHAT TYPES OF ANALOGUE INSULIN ARE AVAILABLE?
Analogue insulin is available in two main forms, rapid acting and long acting, as well as premixed combinations.
Examples of analogue insulin:
- Rapid acting: Humalog, NovoRapid
- Long acting: Lantus, Levemir, Tresiba
- Premixed analogue insulins: Humalog Mix 25, Humalog Mix 50, NovoMix 30
WHAT ARE PREMIXED ANALOGUE INSULINS?
Premixed analogue insulins combine a ratio of rapid acting and long acting insulin.
For example, Humalog Mix 25 consists of 25% rapid acting and 75% long acting insulin.
HOW QUICKLY DO ANALOGUE INSULINS ACT?
Rapid acting insulins start to act immediately after injecting , with their peak action occurring within the first hour after injecting.
The duration is up to 4 hours.
Long acting insulin takes about 2 hours to start acting, and is designed to act uniformly so that there is no peak activity as such. The duration of long acting insulin is up to 24 hours. Your healthcare team will be able to advise whether you need one or two doses per day.
BENEFITS OF ANALOGUE INSULIN
The primary benefits of analogue insulin are that the rapid acting insulin works as soon as it is injected and long acting insulins have no peak activity.
Rapid acting insulin is particularly useful for people who are insulin dependent as it can help to minimise sharp rises (spikes) in blood sugar shortly after eating.
Long acting analogue insulins have become popular partly because the lack of a peak activity period allows for easier prediction of how it acts and has also gives some people more confidence that they will avoid night time hypos
DISADVANTAGES OF ANALOGUE INSULIN
As with human insulins, it has been reported that analogue insulins may lead to unwanted side effects such as loss of hypo awareness, lethargy and weight gain that might not be found when taking animal insulins.
To date, no conclusive research to confirm or deny this claim is available. Analogue insulins are still a relatively new treatment and therefore there is a lack of long term research. In 2009, a four country study highlighted a potential link between the use of Lantus and the development of cancer
However, after the research was reviewed, the European Medicines Agency found the studies to not be consistent enough to either confirm or deny the link, and therefore cleared Lantus as being safe for use.
PRICE OF ANALOGUE INSULIN
A further disadvantage of analogue insulin is in its price. Analogue insulins cost the NHS over twice as much as non-analogue human insulins.
Follow Tom On:
- Links To And Excerpts From 2019 “Approach to the Diagnosis and Management of Subarachnoid Hemorrhage” From WestJEM
- Link To YouTube Video “Conducting a Telemedicine Neurologic Exam’
- Links To And Excerpts From Resources On Posterior Circulation Ischemic Stroke
- Links To Three Excellent Posts On Emergency Department Neuroimaging From NUEM Blog
- Link To The Core EM podcast Episode 175.0 – Posterior Circulation Stroke With An Additional Resource On The HINTS Exam
- This Pathway Is For Outpatient Heart Failure: Links To And Excerpts From “2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction” With Links To Additional Resources
- Links To And Excerpts from The 2019 ACC Decision Pathway On Patients Hospitalized With Heart Failure
- Links To Three New York Times Articles Reviewing The Causes Of Asset and Income Inequality With Additional Resources
- Links To And Excerpts From PedsCases’ Approach to Cyanosis in a Neonate
- “Cyanotic Congenital Heart Disease” From PedsCases
- Link To The Podia YouTube Video “How to make webinar slides – FREE & EASY”
- Links To And Excerpts From Resources On Laryngospasm
- Links To The “IBCC chapter & cast – Vocal Cord Dysfunction” by Dr Josh Farkas
- Links To The “IBCC chapter & cast – Epiglottitis July 2, 2020 by Dr Josh Farkas
- Home Based Patient Monitoring
- YouTube Video “Sedation And Anelgesia For The Non-Intensivist”
- Links To YouTube Videos On How To Use Zoom For Webinars
- Links To and Excerpts From The Awesome Curbsiders’ Post “#206 Airway Management for the Non-Intensivist” With Additional Resources
- YouTube Video “IV Vasoactive Medication Basics for the Non-Intensivist” From The COVID-19 Toolbox
- Two YouTube Videos on How To Use Zoom
- Plan To Link To And Excerpt From Acute Decompensated Heart Failure Update On Hold
- Links To And Excerpts From Dr. Farkas’ “IBCC chapter & cast – Pneumocystis Jirovicii Pneumonia”
- Links To And Excerpts From The Internet Book Of Critical Care Chapter: Vocal Cord Dysfunction
- Links To And Excerpts From Productivity And Time Management Articles From The New York Times
- Links To And Excerpts From “5 Pearls On Inpatient Heart Failure” From CoreIM
- Links To The Outstanding COVID-19 Toolbox
- A List Of Thyroid Diseases With Links To emedicine.medscape.com – A Reliable Online Information Source
- Links To And Excerpts From SGEM #296 – She’s Got The Fever But Does She Need An LP, Antibiotics, Or Admission
- Link To And Excerpts From Clinical Practice Guidelines On Pediatric Lumbar Puncture From The Royal Children’s Hospital Melbourne
- Analysis Of An Abnormal Basic Metabolic Profile